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Summary Purpose Telatinib is an orally active small-
molecule tyrosine kinase inhibitor of kinase insert domain
receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4
(FLT4; VEGFR-3). This study aims at the identification of
relationships between single nucleotide polymorphisms
(SNPs) in genes encoding for transporter proteins and
pharmacokinetic parameters in order to clarify the significant
interpatient variability in drug exposure. In addition, the
potential relationship between target receptor polymorphisms
and toxicity of telatinib is explored. Methods Blood samples
from 33 patients enrolled in a phase I dose-escalation study
of telatinib were analyzed. For correlation with dose
normalized AUC(0–12), ATP-binding cassette (ABC) B1
(ABCB1), ABCC1, and ABCG2 were the genes selected.
For correlation with telatinib toxicity, selected genes were
the drug target genes KDR and FLT4. Results No association
between dose normalized AUC(0–12) and drug transporter
protein polymorphisms was observed. In addition, no
association between toxicity and KDR or FLT4 genotype or
haplotype was seen. Conclusions Our pharmacogenetic
analysis could not reveal a correlation between relevant
gene polymorphisms and clinical and pharmacokinetic
observations of telatinib.
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Introduction
Single nucleotide polymorphisms (SNPs) in genes encoding
for drug transporters and drug targets contribute to
interindividual heterogeneity of drug efficacy and toxicity
in cancer therapy [1, 2]. This type of research is referred to
as pharmacogenetics. In our current study we analyze
pharmacogenetic factors likely to be involved in telatinib
disposition and mechanism of action.
Telatinib (BAY 57-9352) is an orally active, small-
molecule tyrosine kinase inhibitor of kinase insert domain
receptor (KDR; vascular endothelial growth factor receptor
(VEGFR)-2) and fms-related tyrosine kinase 4 (FLT4;
VEGFR-3). Telatinib is metabolized by various cytochrome
P450 (CYP) isoforms including CYP3A4/3A5, CYP2C8,
CYP2C9, and CYP2C19 as well as by uridine diphosphate
glucuronosyltransferase 1A4 (UGT1A4), with the formation
of the N-glucuronides of telatinib as the major biotransfor-
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mation pathway in man. In vitro studies showed telatinib to
be a weak substrate of the adenosine triphosphate binding
cassette (ABC) B1 (ABCB1) transporter (data on file at
Bayer Pharmaceuticals Corporation) [3].
In a phase I and pharmacological study we showed that
pharmacokinetics (PK) of telatinib were dose proportional [4].
However, substantial interpatient variability was observed
(Cmax and AUC(0–12) % coefficient of variation 20–150%)
and no clear association between telatinib exposure and
toxicity could be established. However, in this class of agents
an increase in toxicity is generally observed with increasing
dose [5, 6]. Although in general limited information on drug
metabolism and toxicity is available in early stages of drug
development, pharmacogenetic research may be valuable.
For example, if significant side effects could be linked to a
certain drug transporter polymorphism, this could influence
further drug development or could become an important
issue in patient selection.
The current study examines the potential relationships
between SNPs in genes coding for transporter proteins and
pharmacokinetic parameters of telatinib in order to identify
factors contributing to the significant interpatient variability in
drug exposure. In addition, this study explores the potential
relationship between target receptor polymorphisms and
toxicity of telatinib.
Methods
This study was conducted in a subset of patients enrolled
into a two-centre, phase I dose-escalating study of telatinib
[4]. The aim of this exploratory pharmacogenetic study was
to identify possible relationships between SNPs in genes
coding for drug transporters and PK parameters; and drug
target related SNPs and side effects of telatinib. From 33 of
the 53 patients treated in the phase I study residual blood
samples were available for pharmacogenetic analyses.
Demographic, toxicity and pharmacokinetic characteristics
were comparable for included and excluded patients (data
not shown). Four of these 33 patients were treated with
telatinib oral solution or 25 mg tablets, the remaining
patients with 150 mg tablets.
Since bioavailability of the telatinib formulations differ,
a decision was made to restrict the current analysis to one
telatinib formulation. Therefore, in the association analysis
with PK, only the 29 patients treated with the 150 mg
tablets were included.
Patients and samples
Eligibility criteria, drug administration procedures and
clinical and pharmacokinetic results are described in detail
elsewhere [4]. Briefly, patients with histologically or
cytologically confirmed advanced or metastatic solid
tumors for whom no standard therapy was available, with
an Eastern Cooperative Oncology Group (ECOG) perfor-
mance status ≤2 were eligible. Telatinib was administered
orally, once daily (od) or twice daily (bid), on a continuous
basis. The clinical trial had a standard 3 + 3 phase I dose
escalation study design. Because of significant interpatient
variability in pharmacokinetics the decision was made to
expand all cohorts to a minimum of six patients from the
second cohort onwards. Response evaluation was per-
formed every 2 cycles and was assessed according to
RECIST [7].
Residual blood samples taken for the routine patient care
were stored at −20°C at the local hospital laboratories. One
frozen blood sample for each patient was collected from the
two participating hospitals (Leiden University Medical
Center, Leiden and Erasmus Medical Center, Rotterdam).
All samples were anonymized by a third party, according to
the instructions given in the “Code of Conduct for the use
of data in Health Research” and “Code for Proper
Secondary Use of Human Tissue” (www.federa.org).
Approval from the institutional medical ethical review
boards was obtained.
Pharmacokinetic and toxicity parameters
PK evaluation was performed by collecting blood samples
on days 1 and 14 of cycle 1, and day 14 of cycles 2 and 4.
Pharmacokinetic parameters were calculated by non-
compartmental analysis using WinNonlin (version 4.1.a).
In this study cycle 1 day 14 (representing steady-state)
dose normalized AUC(0–12), calculated as AUC(0–12)/actual
dose administered, was selected as the most important PK
parameter to associate with transporter genetic polymor-
phisms. Dose normalized Cmax, Tmax and T1/2 were also
selected for association analyses.
Patients were evaluated for adverse events and toxicity
according to the National Cancer Institute Common
Toxicity Criteria (NCI-CTC), version 3.0. In general, the
NCI-CTC toxicity score distinguishes between mild
(grade 1), moderate (grade 2), severe (grade 3), life-
threatening or disabling toxicity (grade 4) and death
related to adverse events (grade 5). Telatinib administra-
tion resulted in limited toxicity. Grade 3–4 toxicity was
only seen in 3 patients. Therefore, despite the fact that
grade 3–4 toxicity is more clinically relevant, the
occurrence of any grade 1–4 toxicity was considered to
be the best candidate parameter for association analyses
with drug target receptor genetic polymorphisms. Since
toxicity observed in the first cycle was limited we decided
to use overall toxicity observed in all treatment cycles for
statistical association studies. In addition, hypertension is
considered to be one of the more serious telatinib side
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effects, and grade 1–4 hypertension was also selected for
association analyses.
Selection of candidate genes
Candidate genes were selected based on the information of
preclinical pharmacology studies as reported in the Inves-
tigator’s brochure (Bayer Pharmaceutical Corporation, data
on file). For association with PK parameters ABCB1, ABCC1,
and ABCG2 were the genes selected. For correlation with
telatinib toxicity selected genes were the drug target genes
encoding KDR and FLT4. For the major biotransformation
pathway in man, the formation of the N-glucuronides
through UGT1A4, no SNP met the criteria for selection
described below.
The SNPs were selected, taking into consideration one or
more of the following criteria: validated SNP assay, SNP
causes preferably non-synonymous amino acid change,
indications for clinical relevance from previous publications,
and a preferred minor genotype frequency of ~10%.
DNA extraction and SNP analysis methods
DNA was isolated from whole blood samples with MagNA
Pure DNA Isolation kit (Roche Diagnostics, Almere, The
Netherlands). DNA concentrations were quantified using a
NanoDrop spectrophotometer (Isogen, IJsselstein, The
Netherlands). Taqman assays were obtained from Applied
Biosystems (Applied Biosystems, Nieuwerkerk aan den
IJssel, The Netherlands). As a quality control, 4 samples were
genotyped in duplicate for all assays and 2 assays were tested
in duplicate on all samples. As negative controls water was
used. Overall, no inconsistencies were observed in the results.
The following SNPs were analyzed: ABCB1 3435C>T
(rs1045642), ABCB1 1236C>T (rs1128503), ABCB1
2677G>A/T (rs2032582), ABCB1 -129T>C, ABCC1 C>G
(rs129081), ABCC1 825T>C (rs246221), ABCC1 1062T>C
(rs35587), ABCC1 2012G>T (rs45511401), ABCG2
346G>A (rs2231137), ABCG2 421C>A (rs2231142),
FLT4 1480A>G (rs307826), FLT4 2670C>G (rs448012),
KDR 1719A>T (rs1870377), KDR -604T>C (rs2071559),
and KDR 1192G>A (rs2305948).
SNP genotyping was performed with BIOMARK 48.48
dynamic array (Fluidigm Corporation, South San Francisco,
CA, USA). All assays were performed according to
protocols provided by the manufacturer.
Statistical analysis
Differences in pharmacokinetic and toxicity parameters
among genotypes were analyzed by Student’s t-test, ANOVA
or Kruskal–Wallis test for continuous variables or chi-square
test for dichotomous variables where appropriate. For
toxicity, differences in genotype distribution were tested by
3×2 cross-tabulations for each genotype, and by 2×2 cross-
tabulations for carriers versus noncarriers, with analysis by
2-sided chi-square test.
Polymorphisms within a gene were tested with the chi-
square test (P-value<0.05) to detect linkage disequilibrium
(LD). If LD between SNPs was detected, haplotypes were
determined for each individual with gPLINK (http://pngu.
mgh.harvard.edu/purcell/plink/) [8]. No phase uncertainty
in the defined haploblocks and haplotypes (Rh^2> 0.98)
was seen.
Associations between the number of copies of a haplotype
and clinical parameters were performed using a chi-square test
for dichotomous variables and Student’s t-test, ANOVA or
Kruskal–Wallis test for continuous variables.
Table 1 Patient characteristics, overall telatinib-induced toxicity,
pharmacokinetic results and outcome data of telatinib treated patients





Mean (range) 53 (22–77)
Tumor type
Soft tissue sarcoma 9 (27)
Colorectal cancer 5 (15)
Adrenal cancer 3 (9)
Ovarian cancer 3 (9)
Cholangiocarcinoma 2 (6)






Nr of previous treatment lines
Mean (range) 3 (0–13)
Toxicity
Any toxicity grade 1–4 23 (70)
Any toxicity grade 3 or 4 3 (9)
Hypertension grade 1–4 7 (21)
Hypertension grade 3 or 4 2 (6)
Pharmacokinetic parameters
Mean (range)
Dose normalized AUC(0–12) (µg.hr/L per mg
of dose)
9.26 (0.98–34.60)
Number of treatment courses
Mean (range) 5.5 (1–30)
ECOG Eastern Cooperative Oncology Group, Dose normalized AUC:
area under the curve/dose
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All statistical analyses were performed using SPSS 16.0
software (SPSS, Chicago, IL) and were two-sided, with a
level of significance of α=0.05.
Results
Baseline patient characteristics, observed treatment-related
toxicities, pharmacokinetics and treatment duration are
presented in Table 1. Telatinib doses used were 20 mg od
(n=2), 75 mg od (n=2), 150 mg bid (n=4), 300 mg bid
(n=4), 600 mg bid (n=3), 900 mg bid (n=16), and
1,500 mg bid (n=2). Our population comprised 100%
Caucasians with 45% males and 55% females. Most
frequent tumor types were soft tissue sarcomas (27%) next
to colorectal cancer (15%) together with a high number of
other tumor types (58%) consistent with the phase I nature
of the clinical study. Median number of treatment courses
was 5.5, ranging from 1 to 30, with one course being
3 weeks of telatinib administration.
Dose normalized AUC
Gene Polymorphism Genotype No. Mean SD
ABCB1 3435C>T CC 7 7.30 3.35
CT 16 11.10 9.10
TT 6 6.65 4.76
P-value 0.343
1236C>T CC 9 7.84 3.26
CT 15 11.60 9.44
TT 5 4.82 1.81
P-value 0.180
2677G>A/T GG 9 7.84 3.26
TG 15 11.60 9.44
TT 5 4.82 1.81
P-value 0.180
-129T>C TT 26 8.67 7.51
TC 2 15.65 6.06
CC 1 11.79 n.a.
P-value 0.134
ABCC1 #(rs129081) CC 5 10.22 7.57
GC 15 10.44 9.07
GG 9 6.77 3.16
P-value 0.494
825T>C TT 18 8.26 6.54
TC 11 10.90 8.76
P-value 0.362
1062T>C TT 17 8.36 6.73
TC 10 9.95 9.15
CC 2 13.45 3.30
P-value 0.631
2012G>T GG 24 8.80 5.89
GT 4 13.46 14.57
TT 1 3.63 n.a.
P-value 0.552
ABCG2 346G>A GG 25 9.78 7.83
AG 4 6.00 2.69
P-value 0.353
421C>A CC 23 8.95 7.96
CA 6 10.48 5.26
P-value 0.661




# =*801 number from termina-
tion codon TGA (5397). 3UTR
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Telatinib toxicity was generally mild, with any grade 1–4
toxicity during all treatment cycles occurring in 23 out of
33 patients (70%). Grade 3–4 toxicity was only observed in
3 patients. Hypertension was the most frequently observed
side-effect (n=7) and was unrelated to dose [9].
The success rates for all genotyping assays were 100%.
Genotype frequencies for 13 of 15 SNPs were in Hardy-
Weinberg equilibrium (P>0.05). ABCB1 -129T>C and
ABCC1 2012G>T did not adhere Hardy-Weinberg equilib-
rium, which was most likely caused by the limited
population size. Genotype frequencies for both SNPs were
in line with previous publications and frequencies reported
in the NCBI database (www.ncbi.nlm.nih.gov).
There was no association between telatinib dose nor-
malized AUC(0–12) and genetic polymorphisms in ABCB1,
ABCC1, or ABCG2 (Tables 2 and 3). Haploblock for
ABCB1 included 3435C>T, 1236C>T, and 2677G>A/T;
haploblock for ABCC1 included 825T>C, and 1062T>C.
Haplotype frequencies for ABCB1 were TTT 0.392, CTT
0.017, TCG 0.093, and CCG 0.498, and for ABCC1 CC
0.197, TC 0.061, and TT 0.724. Also ABCB1 and ABCC1
haplotypes did not show an association with telatinib dose
normalized AUC(0–12). There was also no association
between genetic polymorphisms in ABCB1, ABCC1, or
ABCG2 and other investigated PK parameters, i.e. dose
normalized Cmax, Tmax and T1/2 (Tables 2 and 3).
The number of telatinib treatment courses was not
related to any of the genetic polymorphisms and haplotypes
analyzed. Since this was an exploratory study with a
relatively small number of patients, different dose levels,
Toxicity: any toxicity grade 1–4 all cycles
Gene Polymorphism Genotype No Yes P-value
FLT4 1480A>G AA 7 20 0.336
AG 3 3
2670C>G CC 6 11 0.813
CG 3 9
GG 1 3
KDR 1719A>T AA 1 1 0.809
TA 4 9
TT 5 13
-604T>C CC 3 7 0.870
CT 5 13
TT 2 3
1192G>A CC 5 19 0.091
TC 4 4
TT 1 0
Table 4 Association between
genetic polymorphisms and
telatinib-induced toxicity
Table 3 Association between genetic polymorphisms and telatinib pharmacokinetic data. Dose normalized Cmax, T1/2 and Tmax
P-value
Gene Polymorphism Dose normalized Cmax T1/2 Tmax
ABCB1 3435C>T 0.474 0.069 0.274
1236C>T 0.220 0.586 0.597
2677G>A/T 0.220 0.586 0.597
−129T>C 0.140 0.236 0.350
ABCC1 #(rs129081) 0.962 0.393 0.618
825T>C 0.152 0.465 0.582
1062T>C 0.180 0.661 0.705
2012G>T 0.313 0.891 0.721
ABCG2 346G>A 0.253 0.705 0.627
421C>A 0.498 0.399 0.280
# =*801 number from termination codon TGA (5397). 3UTR
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different tumor types, and variable previous treatment lines
association analyses between polymorphisms and treatment
outcome were not performed.
No association between any grade 1–4 toxicity and KDR
or FLT4 genotype or haplotype was observed (Table 4).
Discussion
The development of tailor-made pharmaceutics is especially
useful in the field of oncology, as most standard anticancer
agents have a very narrow therapeutic index, leading to
nonspecific anti-tumor response in combination with a high
level of side effects. For example, in 3–5% of patients with
severe 5-FU-related toxicity. dihydropyrimidine dehydroge-
nase (DPD) deficiencies are described [10, 11]. In addition,
the genetic variant of the gene encoding UDP glucuronosyl-
transferase (UGT) 1A1 polymorphism, UGT1A1*28, is
associated with a higher incidence of toxicity, mostly
hematological toxicity, in irinotecan treatment [12–14].
Most research to improve cancer treatment through
genetics has focused on polymorphisms in genes encoding
the drug transporters and drug metabolizing enzymes but
less is known about genetic variation in drug targets.
Directing treatment on the vascular endothelial growth
factor (VEGF) pathway, one of the key players in
angiogenesis, is a focus of more recent research. VEGF
inhibitors have only become available for clinical use in the
last few years and consequently, very little is known
regarding the influence of polymorphisms in VEGF or its
receptor, VEGFR [15, 16]. One CA repeat polymorphism
in the KDR (VEGFR2)) gene is described previously, with a
higher promoter activity in the 11-repeat polymorphism
compared to the 12-repeat polymorphism [17]. Four SNPs
in the KDR gene were identified by Park et al (-92G>A,
54A>G, 889G>A, and 1416T>A) and associated with
atopy [18]. Recently, Schneider et al reported that KDR
genotypes were not associated with toxicity or efficacy of
paclitaxel with or without bevacizumab treatment in
advanced breast cancer patients [19].
VEGF inhibitors can induce very specific side effects
which are hard to predict. This is even more relevant while
in future use these angiogenesis inhibitors most likely will
be combined with various chemotherapeutic agents. Phar-
macogenetic research might help to identify the patients at
risk for specific side effects and select patients or doses
needed for optimal treatment without adding potentially
harmful side effects.
In this exploratory study we could not find an association
between polymorphisms in genes encoding transporter
proteins and telatinib pharmacokinetics or between drug
target gene polymorphisms and telatinib induced toxicity.
This lack of association might be explained by, for example,
the limited number of patients, the relatively limited toxicity,
and the variability in tumor types, number of previous
treatment lines, and performance scores. Since toxicity was
limited we used toxicity reported over all treatment cycles.
This may have caused bias, and therefore number of treatment
cycles was used as a covariate in the multivariate analysis.
Since different telatinib doses were used, we corrected by
associating polymorphisms with dose normalized AUC(0–12).
Pharmacogenetic testing is important for all new drug
applications. Knowledge on pharmacokinetics and pharma-
codynamics of both registered and new developing drugs is
increasing far more rapidly than the knowledge on genetic
variants in metabolizing enzymes, transporters and drug
target genes [1, 20, 21]. Therefore, DNA collection for
future genetic studies, retrospective and prospective, is
required and all patients in clinical trials should be asked to
consent for DNA collection for future studies. Often side
effects are based on single gene polymorphisms affecting
drug metabolism, interaction with cellular targets or
transport. Therefore, hypothesis based pharmacogenetic
research of candidate genes is important in phase I and II
studies to limit the number of patients unnecessarily
exposed to a toxic dose or drug. This information may reduce
the size, costs and duration of subsequent phase III studies.
In general, in the preclinical and phase I setting little
is known about drug pharmacokinetics and pharmacody-
namics. With this exploratory study we tried to increase that
knowledge, because, despite of the rapidly increasing use of
VEGF inhibitors, the knowledge of determinants that
predict response and toxicity in the individual patient is
still lacking. Therefore, it remains highly important to
conduct pharmacogenetic association studies in early drug
development in order to increase knowledge on interpatient
variability of drug response.
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